Hansen, Anne S.
Rask, Charlotte U.
Rodrigo-Domingo, Maria
Pristed, Sofie G.
Christensen, Jakob
Nielsen, René E.
Article History
Received: 27 February 2020
Revised: 10 April 2020
Accepted: 11 April 2020
First Online: 11 May 2020
Competing interests
: J.C. has received honoraria for serving on the Scientific Advisory Board of Union Chimique Belge (UCB) Nordic and Eisai AB and for giving lectures for UCB Nordic and Eisai, as well as travel funds from UCB Nordic and funding by the Novo Nordisk Foundation (grant number: NNF16OC0019126), the Central Denmark Region and the Danish Epilepsy Association. R.E.N. has received research grants from H. Lundbeck and Otsuka Pharmaceuticals for clinical trials, has received speaking fees from Bristol-Myers Squibb, Astra Zeneca, Janssen & Cilag, H. Lundbeck, Servier, Otsuka Pharmaceuticals, Teva and Eli Lilly, and has acted as advisor to Astra Zeneca, Eli Lilly, Lundbeck, Otsuka Pharmaceuticals, Takeda and Medivir. The remaining authors have no financial relationships relevant to this article to disclose. All authors have no competing interests relevant to this article to disclose.
: The study received financial support from the Clinical Psychiatric Research Fund of the North Denmark Region, the Helsefonden, the Foundation of Aase and Ejnar Danielsen, the Psychiatric Research Fund of 1967, and the Foundation of Slagtermester Wørzner and Wife Inger Wørzner.
: Not required. The Danish Data Protection Agency (ID: 2016–164), the Danish Health Data Authority (FSEID: 00002709), and the Danish Health Authority (ID: 3–3013–1859) approved the study and data use.